PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19435893-1 2009 Knockdown of the tumor suppressor phosphatase Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) with shRNA in three estrogen receptor (ER)-positive breast cancer cell lines resulted in increased phosphatidylinositol-3 kinase (PI3K) and AKT activities, resistance to tamoxifen and fulvestrant, and hormone-independent growth. Tamoxifen 281-290 phosphatase and tensin homolog Homo sapiens 105-109 19435893-3 2009 Tamoxifen and fulvestrant treatment inhibited estradiol-induced ER transcriptional activity in all shPTEN cell lines but did not abrogate the increased cell proliferation induced by PTEN knockdown. Tamoxifen 0-9 phosphatase and tensin homolog Homo sapiens 101-105 34978016-12 2022 CONCLUSION: Low PTEN expression and high methylation of its promoter (sequence - 819 to - 787 bp) in tissue predict poor DFS and OS in hormone receptor-positive early BC patients who received adjuvant TAM. Tamoxifen 201-204 phosphatase and tensin homolog Homo sapiens 16-20 18500270-3 2008 The aim of our study was to seek a possible correlation between endometrial carcinoma, tamoxifen exposure and MSI, PTEN, beta-catenin and K-ras abnormalities. Tamoxifen 87-96 phosphatase and tensin homolog Homo sapiens 115-119 18500270-13 2008 Patients with tamoxifen exposure had more K-ras mutations and fewer PTEN mutations and MSI as opposed to controls, but the results were not statistically significant. Tamoxifen 14-23 phosphatase and tensin homolog Homo sapiens 68-72 15475931-0 2005 Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Tamoxifen 86-95 phosphatase and tensin homolog Homo sapiens 8-12 15475931-6 2005 Decreased PTEN and/or increased protein kinase B/Akt activity in breast cancer cells has recently been associated with resistance to tamoxifen-induced apoptosis. Tamoxifen 133-142 phosphatase and tensin homolog Homo sapiens 10-14 15475931-7 2005 In this study, we have evaluated PTEN expression by immunohistochemistry in 100 tamoxifen-treated ER-alpha-positive breast cancer patients. Tamoxifen 80-89 phosphatase and tensin homolog Homo sapiens 33-37 15475931-11 2005 In summary, our results showed a strong association between downregulation of PTEN expression in ER-alpha-positive tumors and failure to tamoxifen treatment. Tamoxifen 137-146 phosphatase and tensin homolog Homo sapiens 78-82 15589576-8 2005 RESULTS: Of 29 tamoxifen-associated cancers, 10 (34.5%) contained PTEN mutations compared to 13 (44.8%) of the non-tamoxifen-associated cancers (P = 0.59). Tamoxifen 15-24 phosphatase and tensin homolog Homo sapiens 66-70 34978016-0 2022 PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy. Tamoxifen 133-142 phosphatase and tensin homolog Homo sapiens 0-4 34978016-2 2022 In vitro experiments have shown that downregulation of PTEN expression leads to resistance to tamoxifen (TAM) in BC cells. Tamoxifen 94-103 phosphatase and tensin homolog Homo sapiens 55-59 34978016-2 2022 In vitro experiments have shown that downregulation of PTEN expression leads to resistance to tamoxifen (TAM) in BC cells. Tamoxifen 105-108 phosphatase and tensin homolog Homo sapiens 55-59 18814240-9 2008 Functional kinetic studies following tamoxifen treatment of the PTEN mutated RL95-2 EnCa cell line, demonstrated a doubling of phosphorylation of pERalpha-Ser118 and a 4.2-fold induction of pAKT-Thr308 along with Syncytin-1 induction. Tamoxifen 37-46 phosphatase and tensin homolog Homo sapiens 64-68 17914589-9 2007 The apoptotic effect of receptor-targeting drugs (tamoxifen, trastuzumab, ZD1839) was dependent both on receptor expression and PTEN expression. Tamoxifen 50-59 phosphatase and tensin homolog Homo sapiens 128-132 12530022-0 2002 PTEN expression in tamoxifen-associated endometrial cancers. Tamoxifen 19-28 phosphatase and tensin homolog Homo sapiens 0-4 12530022-4 2002 This study evaluates PTEN immunohistochemical (IHC) expression in tamoxifen-associated endometrial cancers. Tamoxifen 66-75 phosphatase and tensin homolog Homo sapiens 21-25 12530022-9 2002 Four out of 15 (27%) tamoxifen users expressed PTEN compared with 2 out of 13 (15%) of non-users. Tamoxifen 21-30 phosphatase and tensin homolog Homo sapiens 47-51 12530022-10 2002 CONCLUSION: In this study, it appears that tamoxifen-associated endometrial cancers are not significantly different from sporadic endometrial cancer with regards to PTEN IHC expression, although there is a trend towards retained PTEN expression. Tamoxifen 43-52 phosphatase and tensin homolog Homo sapiens 229-233 33318536-0 2020 Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells. Tamoxifen 108-117 phosphatase and tensin homolog Homo sapiens 25-29 33318536-2 2020 In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using gradually increased doses of tamoxifen in one model, while fixing tamoxifen treatment dose at 35 muM for several times in the second model. Tamoxifen 169-178 phosphatase and tensin homolog Homo sapiens 71-75 33318536-6 2020 These genes" upregulation was accompanied by PTEN and GSK3 ss genes" down-regulation, and it was in correlation to the changes in the metabolic rate of glucose in tamoxifen-resistant models. Tamoxifen 163-172 phosphatase and tensin homolog Homo sapiens 45-49 33318536-2 2020 In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using gradually increased doses of tamoxifen in one model, while fixing tamoxifen treatment dose at 35 muM for several times in the second model. Tamoxifen 101-110 phosphatase and tensin homolog Homo sapiens 71-75 33318536-2 2020 In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using gradually increased doses of tamoxifen in one model, while fixing tamoxifen treatment dose at 35 muM for several times in the second model. Tamoxifen 169-178 phosphatase and tensin homolog Homo sapiens 71-75 26418898-1 2016 We previously showed that S-adenosylmethionine-mediated hypermethylation of the PTEN promoter was important for the growth of tamoxifen-resistant MCF-7 (TAMR-MCF-7) cancer cells. Tamoxifen 126-135 phosphatase and tensin homolog Homo sapiens 80-84 33173749-4 2020 Furthermore, it is discovered that CD63+ CAFs secrete exosomes rich in miR-22, which can bind its targets, ERalpha and PTEN, to confer tamoxifen resistance on breast cancer cells. Tamoxifen 135-144 phosphatase and tensin homolog Homo sapiens 119-123 31604073-0 2020 Knockdown of PTEN decreases expression of estrogen receptor beta and tamoxifen sensitivity of human breast cancer cells. Tamoxifen 69-78 phosphatase and tensin homolog Homo sapiens 13-17 31604073-1 2020 Estrogen receptors (ERs) and the PTEN-Akt-mTor pathway are important growth regulators in human breast cancer cells, which both are known to affect response to tamoxifen therapy. Tamoxifen 160-169 phosphatase and tensin homolog Homo sapiens 33-37 31604073-7 2020 Importantly, treatment with ER beta agonist DPN (5 nM) significantly decreased the inhibitory effect of a PTEN knockdown on tamoxifen response of both cell lines (p<0.05). Tamoxifen 124-133 phosphatase and tensin homolog Homo sapiens 106-110 31604073-9 2020 The data of previous studies reporting an important role of ER beta in tamoxifen sensitivity and our findings suggest down-regulation of ER beta triggered by PTEN knockdown contributed to the decreased response of breast cancer cells to tamoxifen observed in this study. Tamoxifen 237-246 phosphatase and tensin homolog Homo sapiens 158-162 30573703-0 2018 The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy. Tamoxifen 36-45 phosphatase and tensin homolog Homo sapiens 119-123 21170675-0 2011 Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Tamoxifen 37-46 phosphatase and tensin homolog Homo sapiens 8-12 25882671-6 2015 In an effort to overcome the resistance, intensive research has been conducted to understand the underlying mechanisms; this has resulted in the identification of complex factors/pathways contributing to tamoxifen resistance, including modulations of the ERsignaling, upregulation of a set of growth factor receptor networks (HER2, EGFR, FGFR, and IGF1R), alterations of the PI3K-PTEN/AKT/mTOR pathway, and an elevation of the NF-kappaB signaling. Tamoxifen 204-213 phosphatase and tensin homolog Homo sapiens 380-384 24853176-8 2014 These observations alongside the mutational spectrum in PTEN suggest that the malignancies arise from different backgrounds, hence pointing to an effect of tamoxifen. Tamoxifen 156-165 phosphatase and tensin homolog Homo sapiens 56-60 23515291-7 2013 Silencing IGFBP-2 had no effect on the response to IGF-II, but responses to estrogen and tamoxifen were no longer observed due to loss of ER-alpha, which could be prevented by the inhibition of PTEN. Tamoxifen 89-98 phosphatase and tensin homolog Homo sapiens 194-198 22892847-0 2012 The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Tamoxifen 68-77 phosphatase and tensin homolog Homo sapiens 14-18 22892847-4 2012 The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. Tamoxifen 117-126 phosphatase and tensin homolog Homo sapiens 63-67 22892847-4 2012 The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. Tamoxifen 269-278 phosphatase and tensin homolog Homo sapiens 63-67 22892847-10 2012 In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen. Tamoxifen 152-161 phosphatase and tensin homolog Homo sapiens 42-46 21170675-8 2011 These results suggest that methylation of the PTEN promoter related to both SAM increase and DNMT1 activation contributes to persistent Akt activation and are potential therapeutic targets for reversing TAM resistance in breast cancer. Tamoxifen 203-206 phosphatase and tensin homolog Homo sapiens 46-50 21674849-0 2011 PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen. Tamoxifen 119-128 phosphatase and tensin homolog Homo sapiens 0-4 21674849-8 2011 CONCLUSION: Our results suggest that PTEN protein expression might be of prognostic significance in postmenopausal SR(+) BC patients treated with adjuvant tamoxifen. Tamoxifen 155-164 phosphatase and tensin homolog Homo sapiens 37-41